Shining a LIGHT on myeloid cell targeted immunotherapy

Despite over a decade of clinical trials combining inhibition of emerging checkpoints with a PD-1/L1 inhibitor backbone, meaningful survival benefits have not been shown in PD-1/L1 inhibitor resistant or refractory solid tumours, particularly tumours dominated by a myelosuppressive microenvironment....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2023-07, Vol.187, p.147-160
Hauptverfasser:	Shuptrine, Casey W., Perez, Vincent M., Selitsky, Sara R., Schreiber, Taylor H., Fromm, George
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired resistance Checkpoint inhibition Co-stimulation Cytokines Humans HVEM Immunotherapy LIGHT LTβR Lymphotoxin beta Receptor Myeloid Cells Myeloid therapy Neoplasms - drug therapy Programmed Cell Death 1 Receptor Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!